Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.31 |
| ▸ | TERT | O14746 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30269173 | 0.81 | TERT (0.40) | SLC1A2TERT | |
| SCHEMBL17841877 | 0.81 | TERT (0.40) | SLC1A2TERT | |
| SCHEMBL10037571 | 0.78 | POLB (0.37) | POLBSLC1A2MAPT | |
| SCHEMBL13185397 | 0.78 | POLB (0.37) | POLBSLC1A2MAPT | |
| SCHEMBL13448309 | 0.77 | POLB (0.35) | POLBSLC1A2 | |
| SCHEMBL2610530 | 0.76 | POLB (0.36) | POLBSLC1A2MAPT | |
| SCHEMBL10037953 | 0.76 | SLC1A2 (0.30) | SLC1A2 | |
| SCHEMBL10037551 | 0.76 | POLB (0.38) | POLBSLC1A2MAPT | |
| SCHEMBL12107536 | 0.76 | CYP1A2 (0.43) | POLBSLC1A2MAPT | |
| SCHEMBL12421897 | 0.74 | POLB (0.32) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124791-B2 | Active energy ray curable liquid composition and liquid cartridge | CANON KABUSHIKI KAISHA (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20100094024-A1 | ACTIVE ENERGY RAY CURABLE LIQUID COMPOSITION AND LIQUID CARTRIDGE | CANON KABUSHIKI KAISHA (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094024-A1 | ACTIVE ENERGY RAY CURABLE LIQUID COMPOSITION AND LIQUID CARTRIDGE | C9, MLX, CHRM1 | CPB2 1430/4885POLB 207/4885SLC1A2 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.